Dan 🌈
I feel like most in-house software is tacitly released under the Hot Potato Licence.
| Github | https://github.com/jonesnl |
Nate Jones 
- 6 Followers
- 15 Following
- 15 Posts
Bit twiddling software engineer.
> but it does match the overall intent and intended primary use case of passkeys.
For most consumer users, yes the ability to sync, back up, and restore your #passkeys is a good thing for usability. And it should probably be the default for most/all consumer scenarios.
However, defining "passkeys" to exclude device bound authenticators introduces an ecosystem/UI/UX split for little reason. It's the same technology stack top to bottom outside of the implementation details of the authenticator itself.
We can provide the good default user experience of synced passkeys without taking the freedom from security conscious enterprises/users to use Yubikeys on passkey supported websites.
The latter. The standards body talks about the definition here https://fidoalliance.org/passkeys.
If that doesn't answer one of your questions lmk.
@nuxi This standard company tool can't be trusted! 🙃
@nuxi I see the senior security leadership hasn't changed much .
.
SwiftOnSecurityWelcome to Mastodon, for the people who move into an unincorporated area of the county so they don't have to deal with The Man, but then setup a HOA.
👏👏👏
https://www.stoptb.org/news/global-drug-facility-update-access-to-bedaquiline
> Following lengthy negotiations, Johnson & Johnson has granted Stop TB Partnership´s Global Drug Facility`s licenses that enable Global Drug Facility (GDF) to tender, procure, and supply generic versions of SIRTURO® (bedaquiline) for the majority of low-and middle-income countries, including countries where patents remain in effect.
Global Drug Facility Update on Access to Bedaquiline | Stop TB Partnership
13 July 2023 Following lengthy negotiations, Johnson & Johnson has granted Stop TB Partnership´s Global Drug Facility`s licenses that enable Global Drug Facility (GDF) to tender, procure, and supply generic versions of SIRTURO® (bedaquiline) for the majority of low-and middle-income countries, including countries where patents remain in effect. GDF has shared with the TB
